Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Ventyx Biosciences, Inc. (Nasdaq: VTYX), a clinical-stage biopharmaceutical firm, announced participation in key investor conferences. Noteworthy events include the Cowen 43rd Annual Health Care Conference in Boston on March 8, 2023, and the Barclays Global Healthcare Conference in Miami on March 15, 2023, where Ventyx will present from 9:30 to 9:55 AM ET. Additionally, the Jefferies Biotech on the Bay Summit also takes place in Miami on March 16, 2023. A webcast of the Barclays presentation will be available on the Ventyx website for 30 days post-event. Ventyx is dedicated to developing oral therapies for autoimmune and inflammatory diseases.
- None.
- None.
ENCINITAS, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
- Event: Cowen 43rd Annual Health Care Conference
Location: Boston, MA
Date: Wednesday, March 8, 2023
- Event: Barclays Global Healthcare Conference
Location: Miami, FL
Date: Wednesday, March 15, 2023
Time: 9:30-9:55 AM ET
- Event: Jefferies Biotech on the Bay Summit
Location: Miami, FL
Date: Thursday, March 16, 2023
A webcast of the Barclays presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event for thirty days.
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.
Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
FAQ
What is VTYX's participation in the Cowen 43rd Annual Health Care Conference?
When is the Barclays Global Healthcare Conference for VTYX?
Is there a webcast available for VTYX's conferences?
What is the focus of VTYX's drug development?
Where is Ventyx Biosciences headquartered?
